Health Policy
Function
The Working Group on Health Policy deals with business and political parameters, ranging from licensing, paths to reimbursement, market access and care to billing for biopharmaceutical products. More broadly, its work also involves analysing the business policy and health economy policy issues of the legal parameters for Germany as a biotech location.
Co-ordinators
Prof. Dr. Helga Rübsamen-Schaeff
AiCuris Anti-infective Cures GmbH
Prof. Dr. med. Niels Riedemann
InflaRx GmbH
Experts from the following companies
- AbbVie Deutschland GmbH & Co. KG
- AiCuris Anti-infective Cures AG
- Atriva Therapeutics GmbH
- Bayer AG
- Bayerische Patentallianz GmbH
- Berlin Partner für Wirtschaft und Technologie GmbH
- BIO.ASPEKTE
- BIOCOM AG
- D+B Rechtsanwälte Partnerschaft mbH
- EUCOPE - European Confederation of Pharmaceutical Entrepreneurs AISBL
- Exact Sciences Deutschland GmbH
- FGK Clinical Research GmbH
- Formycon AG
- Guardant Health
- InflaRx GmbH
- ITM Medical Isotopes GmbH
- Jones Day
- Medigene AG
- Miltenyi Biotec B.V. & Co. KG
- MorphoSys AG
- NDA Regulatory Service GmbH
- Osborne Clarke
- PricewaterhouseCoopers GmbH WPG
- Sanofi-Aventis Deutschland GmbH
- Sinfonie Life Science Management GmbH
- Synovo GmbH
- Thermo Fisher Scientific
- TME Pharma AG
- Vakzine Projekt Management GmbH